Sinclair IS Pharma PLC  

(Public, LON:SPH)   Watch this stock  
Find more results for Stephen Sinclair
29.25
0.00 (0.00%)
Oct 22 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 28.75 - 30.25
52 week 23.30 - 34.18
Open 29.25
Vol / Avg. 165,308.00/805,294.00
Mkt cap 146.75M*
P/E     -
Div/yield     -
EPS -0.01*
Shares 497.41M
Beta     -
Inst. own     -
*GBP
Nov 3, 2014
Sinclair IS Pharma PLC Annual Shareholder Meeting (Estimated) Add to calendar
Sep 18, 2014
Full Year 2014 Sinclair IS Pharma PLC Earnings Presentation (London)
Sep 18, 2014
Full Year 2014 Sinclair IS Pharma PLC Earnings Release
  

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin -4.44% -6.44%
Operating margin 1.37% -2.81%
EBITD margin - 12.69%
Return on average assets -1.55% -1.78%
Return on average equity -3.14% -3.58%
Employees 144 -
CDP Score - -

Address

1st Floor Whitfield Court 30-32 Whitfield Street
LONDON, ENG W1T 2RQ
United Kingdom - Map
+44-20-74676920 (Phone)
+44-20-74676930 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Sinclair IS Pharma plc is a specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through surface technology and delivery systems. It has presence in five European markets and a marketing partner network across developed and emerging markets. On October 1, 2012, the Company announced that it had entered into a 100 year distribution agreement with Valeant Pharmaceuticals International Inc. for the distribution of injectable aesthetic dermal filler products Sculptra and New-Fill and the sub-distribution of Succeev in Western Europe. In March 2011, the Company launched FlammaSpray for the treatment of sunburn. In November 2013, Sinclair IS Pharma PLC announced the disposal of non-core products Effederm, Xclair, Salinum and SST. In January 2014, Sinclair IS Pharma PLC acquired Obvieline Laboratories SA. In January 2014, Sinclair IS Pharma PLC acquired Atlean, a dermal filler, from Stiefel the dermatology business of GSK.

Officers and directors

Christopher P. Spooner Chief Executive Officer, Executive Director
Age: 43
Alan Olby Chief Financial Officer
Jean-Louis Lamande Operations Finance Director
Christophe H. Foucher Chief Operating Officer, Executive Director
Patrick Khoukaz Head - European Operations and Global Aesthetics
Sarb Klair Head - Corporate Development
Nairn McMaster Head - Business Development
Stephen Redman Company Secretary, Legal Director
Grahame David Cook Non-Executive Independent Chairman of the Board
Jean-Charles Tschudin Senior Non-Executive Independent Director
Age: 71